Phase 2a Win: Intranasal Foralumab Cuts Neuroinflammation in Progressive MS
TLSA is trading near its 52-week low of $0.762 (14% above the low).
Summary
Tiziana's Phase 2a INFORM-MS trial hit both primary endpoints in non-active secondary progressive MS, a disease with no FDA-approved therapy. The 50 μg nasal foralumab arm showed a statistically significant reduction in microglial activation on TSPO PET (p=0.0168), and both doses were safe and well tolerated with no discontinuations or drug-related serious adverse events across 48 patients. Fatigue scores fell 6.17 points at 50 μg and 7.18 at 100 μg versus 3.12 on placebo, though the study was not powered for clinical endpoints and EDSS showed no change over 12 weeks. The 100 μg arm did not reach significance on the PET endpoint, so the imaging win rests on the smaller 50 μg cohort. This lands three weeks after the 6-K confirming last patient last visit, and it matters most because the company reported a $12.4M first-half loss with just $3.9M of cash and going-concern doubt — a positive registrational-path story is the main lever for financing. Next step is an FDA meeting on the path forward in na-SPMS, with full data slated for a scientific congress.
At the time of this announcement, TLSA was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.6M. The 52-week trading range was $0.76 to $1.96. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.